The estimated Net Worth of Michael Douglas Taylor is at least $5.39 Million dollars as of 3 May 2021. Michael Taylor owns over 8,000 units of Deciphera Pharmaceuticals Inc stock worth over $204,720 and over the last 7 years he sold DCPH stock worth over $0. In addition, he makes $5,181,090 as Director at Deciphera Pharmaceuticals Inc.
Michael has made over 22 trades of the Deciphera Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 8,000 units of DCPH stock worth $26,720 on 3 May 2021.
The largest trade he's ever made was exercising 125,000 units of Deciphera Pharmaceuticals Inc stock on 1 October 2020 worth over $236,250. On average, Michael trades about 25,271 units every 30 days since 2017. As of 3 May 2021 he still owns at least 8,000 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Michael Taylor stock trades at the bottom of the page.
Dr. Michael Douglas Taylor serves as Director of the Company. He is an Operating Partner with Mission BioCapital, an early-stage life science venture fund. Dr. Taylor served as our President and Chief Executive Officer from March 2014 until his retirement as Chief Executive Officer in March 2019. Dr. Taylor served as Senior Advisor to Deciphera from March 2019 through September 2019. Prior to joining Deciphera, Dr. Taylor was Chief Executive Officer of Ensemble Therapeutics, Corp., a small molecule drug discovery company, from July 2007 to October 2013. Prior to joining Ensemble, Dr. Taylor was Senior Vice President for Pfizer Inc.’s Global R&D division and served as Vice President, Drug Development at Warner-Lambert/Parke-Davis, where he led early and late-stage development projects across multiple therapeutic areas, including Lipitor® and Neurontin®. Dr. Taylor has authored or co-authored 65 manuscripts and published abstracts and is co-inventor on eight patents. Dr. Taylor holds a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo School of Pharmacy, was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania, and holds a B.S. magna cum laude in chemistry from the University of South Florida.
As the Director of Deciphera Pharmaceuticals Inc, the total compensation of Michael Taylor at Deciphera Pharmaceuticals Inc is $5,181,090. There are 1 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.
Michael Taylor is 65, he's been the Director of Deciphera Pharmaceuticals Inc since 2019. There are 3 older and 13 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar und Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: